Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn(University of California, Los Angeles), Philippe Merle(Hôpital de la Croix-Rousse), Ho Yeong Lim(CHA University Bundang Medical Center), В. В. Бредер, Ann‐Lii Cheng(National Taiwan University), Yee Chao(National Cancer Center), Masatoshi Kudo(Kindai University), Stephen L. Chan(Chinese University of Hong Kong), Erluo Chen, Baek‐Yeol Ryoo(Asan Medical Center), Bruno Daniele(Azienda Ospedaliera G.Rummo), Marcelo Garrido(Pontificia Universidad Católica de Chile), Jennifer J. Knox(National Cancer Center), Julien Edeline(Inserm), Mohamed Bouattour(Hôpital Beaujon), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Thomas Yau(University of Hong Kong), Sadahisa Ogasawara(Chiba University), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1,831
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k